-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Travere Therapeutics, Raises Price Target to $53

Benzinga·04/14/2026 17:19:28
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $48 to $53.